SUMMARY
ALLEGRA-D® 24 HOUR (fexofenadine hydrochloride and pseudoephedrine hydrochloride) Extended-Release Tablets for oral administration contain 180 mg fexofenadine hydrochloride for immediate release and 240 mg pseudoephedrine hydrochloride for extended release.
ALLEGRA-D 24 HOUR Extended-Release Tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. Symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion.
ALLEGRA-D 24 HOUR should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see CLINICAL PHARMACOLOGY).
|
|
NEWS HIGHLIGHTSMedia Articles Related to Allegra-D 24 Hour (Fexofenadine / Pseudoephedrine)
Review Article Examines Sublingual Immunotherapy For Treatment Of Allergic Rhinitis And Asthma
Source: Allergy News From Medical News Today [2013.03.28]
In an examination of a type of treatment for allergic rhinitis and asthma that is used in Europe but not approved by the U.S. Food and Drug Administration, researchers found moderate strength in the evidence from previous studies to support the use of sublingual immunotherapy for the treatment of these conditions, according to an article in the March 27 issue of JAMA...
News From The Annals Of Internal Medicine: Feb. 19, 2013
Source: Complementary Medicine / Alternative Medicine News From Medical News Today [2013.02.20]
1. Acupuncture May be an Effective Alternative for Treating Seasonal Allergies Patients receiving acupuncture treatments for seasonal allergic rhinitis reported statistically significant improvements in symptoms and decreased use of medication compared to patients having standard treatment or sham acupuncture, but the clinical significance of the observed improvements is uncertain...
Clinical Trials Related to Allegra-D 24 Hour (Fexofenadine / Pseudoephedrine)
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge [Recruiting]
An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A
nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic
rhinometry will be used to measure the congestion.
|
|
|
|
Page last updated: 2013-03-28
|
